Tokai, a Cambridge, MA based Pharmaceutical company, just presented a promising set of Phase I data pointing to the early efficacy of its "triple whammy" pill for castration-resistant prostate cancer, TOK-001 or galeterone. In their phase 1 trial the PSA levels in about half of the 49 men in the dose-ranging study declined 30% or [...]
I have had a number of recent conversations with men with advanced prostate cancer who have been taking Abiraterone Acetate (Zytiga). The question that comes up in regular conversation is about knowing when Zytiga has stopped working or when Zytiga should be discontinued. All the real guidance we have to answer this question comes from [...]
According to a study published online May 9 in The American Journal of Pathology copy number variations (CNV) in both malignant and benign prostate tissue is predictive of prostate cancer relapse. The research performed at the University of Pittsburgh School of Medicine by Yan P. Yu, M.D. and colleagues evaluated whether CNV of the genomes [...]
Today, the U.S. Preventive Services Task Force (USPSTF) posted its prostate cancer screening final recommendation statement. The following letter was received by anyone who posted a public comment: The USPSTF is committed to making the recommendations process clear and transparent and we are able to achieve that by keeping the public fully informed throughout the [...]
Radium-223 Chloride (Alpharadin) is now available for the treatment of men with advanced prostate cancer who have symptomatic bone metastases (painful) and who are also castration-resistant (hormone-refractory). This is an expanded access program that will allow the use of Alpharadin prior to the formal FDA approval of the treatment. From the Clinical Trials Web Page [...]